Avastin (bevacizumab)
Avastin is a VEGF-specific angiogenesis inhibitor used, in combination with paclitaxel and cisplatin or paclitaxel and topotecan, for the treatment of patients with persistent, recurrent, or metastatic cervical cancer.
Genentech offers 2 financial assistance programs for patients using Avastin:
Genentech BioOncology Co-pay Assistance Program
Eligible patients with private insurance will pay just a $5 copay per prescription or infusion of
Genentech Patient Foundation
This foundation provides Avastin free of charge to uninsured or underinsured patients whose annual household income is less than $150,000 and who meet specific financial criteria.
Hycamtin (topotecan hydrochloride injection)
Hycamtin for injection is a topoisomerase inhibitor used, in combination with cisplatin, for the treatment of patients with stage IVB, recurrent or persistent carcinoma of the cervix
Novartis’ Patient Assistance NOW Oncology offers 1 financial assistance program for patients using Hycamtin:
Novartis Patient Assistance Foundation
Patients who are experiencing financial hardship and have limited or no public or private prescription coverage may be able to receive Hycamtin for free through the Novartis Patient Assistance Foundation. To be eligible, the patient must be a US citizen, and have an annual household income of up to $75,000 for 1 person; $100,000 for 2 people; $125,000 for 3 people; $150,000 for 4 people; and up to $25,000 more for each additional person in the household. Eligible patients will receive Hycamtin for free for 1 year, or until prescription drug coverage becomes available to them.
Keytruda (pembrolizumab)
Keytruda is a PD-1 inhibitor used for the treatment of recurrent or metastatic cervical cancer progressing during or after chemotherapy in patients whose tumors express PD-L1, as determined by an FDA-approved test.
Merck offers 2 financial assistance programs for patients using Keytruda:
Merck Co-pay Assistance Program
Privately insured patients will pay the first $25 of their copay per Keytruda infusion. The maximum benefit per calendar year is $25,000.
Merck Patient Assistance Program
Patients without insurance or prescription coverage may be eligible to receive Keytruda at no cost. Eligible patients must have a household income of $62,450 or less for individuals, $84,550 or less for a couple, or $128,750 or less for a family of 4. Patients with insurance, including Medicare Part D, who still have trouble paying for their medicines may request that an exception be made, provided their household income is not above a set limit.
Mvasi (bevacizumab-awwb)
Mvasi, a biosimilar to Avastin, is a VEGF inhibitor used, in combination with chemotherapy (with paclitaxel and cisplatin, or with paclitaxel and topotecan), for the treatment of patients with persistent, recurrent, or metastatic cervical cancer.
Amgen offers 2 financial assistance programs for patients using Mvasi:
Amgen FIRST STEP Program
With this program, eligible patients who have private insurance will pay $0 for the first dose of Mvasi and $5 for each subsequent dose, with a maximum annual benefit of $20,000.
Amgen Safety Net Foundation
Patients who have limited or no insurance coverage and patients with Medicare Part D program who satisfy the income eligibility requirements, may receive Mvasi for free
Table. Drugs Prescribed for Cervical Cancer
- Drug name (generic name)
- Drug company
- Indication
- Patient support services
- Avastin (bevacizumab Injection
-
Drug company
- Genentech
- Treatment of recurrent, persistent, or metastatic cervical cancer, in combination with paclitaxel and cisplatin or paclitaxel and topotecan
- Genentech BioOncology Co-pay Assistance Program
855-692-6729
Genentech Patient Foundation
888-941-3331
- Hycamtin (topotecan hydrochloride injection)
- Novartis
- Treatment of stage IVB, recurrent or persistent carcinoma of the cervix, in combination with cisplatin
- Novartis Patient Assistance Foundation
800-277-2254
- Keytruda (pembrolizumab)
- Merck
- Treatment of recurrent or metastatic cervical cancer progressing during or after chemotherapy in patients whose tumors express PD-L1, as determined by an FDA-approved test
- Merck Co-pay Assistance Program
855-257-3932
Merck Patient Assistance Program
855-257-3932
- Mvasi (bevacizumab-awwb)
- Amgen
- Treatment of persistent, recurrent, or metastatic cervical cancer, in combination with chemotherapy
- Amgen FIRST STEP Program
888-657-8371
Amgen Safety Net Foundation
888-762-6436